Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
selonabant · 1 trial · 1 indication
The minimum possible Beck Depression Inventory (BDI) score is 0, and the maximum score is 63. This score is determined by summing the ratings from the 21 questions, with each question scoring from 0 to 3, indicating the severity of depressive symptoms over the past two weeks. Lower score means less depression
The Columbia-Suicide Severity Rating Scale (C-SSRS) does not have a single minimum or maximum score, as it is not a traditional cumulative-score test. Instead, it uses a series of "yes" or "no" questions to place an individual into distinct categories of risk based on their specific responses. Lower score means less suicidal ideation.
Pharmacokinetic clearance (\\(CL\\)) is a quantitative measure of how efficiently the body removes a drug from the bloodstream. It is defined as the volume of plasma from which a drug is completely and irreversibly removed per unit of time and is typically expressed in units like milliliters per minute (mL/min) or liters per hour (L/h).
| Arm | Type | Description |
|---|---|---|
| Experimental Cohort 1 | EXPERIMENTAL | Single intravenous dose of 1 mg of selonabant or placebo |
| Experimental Cohort 2 | EXPERIMENTAL | Single intravenous dose of 2 mg of selonabant or placebo |
| Experimental Cohort 3 | EXPERIMENTAL | Single intravenous dose of 5 mg of selonabant or placebo |
| Experimental Cohort 4 | EXPERIMENTAL | Single intravenous dose of 10 mg of selonabant or placebo |
| Experimental Cohort 5 | EXPERIMENTAL | Single intravenous dose of 20 mg of selonabant or placebo |
| Name | Type | Description |
|---|---|---|
| selonabant | DRUG | Intravenous infusion of selonabant |
| placebo | DRUG | Placebo infusion which looks the same as the selonabant infusion |
Key Inclusion Criteria: 1. The subject is male or female 18 to 30 years of age, inclusive. 2. The subject has a body mass index of 18 to 30 kg/m2, inclusive, and with a minimum weight of 50 kg and maximum weight of 110 kg. 3. The subject has no clinically significant medical history and no clinical...
Selonabant is an investigational small molecule being developed by Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB). It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers, with one completed clinical trial involving 40 participants in the United States.
Selonabant is being studied for use in healthy volunteers. The completed Phase 1 clinical trial, NCT07211607, was titled "I.V. Selonabant in Healthy Adult Subjects" and enrolled 40 participants. The drug is still in early-stage clinical development and has not been approved for any medical condition.
Selonabant is being developed by Anebulo Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol ANEB. The company is conducting clinical trials to evaluate the drug's safety and tolerability in healthy volunteers.
Selonabant is in Phase 1 clinical development. The drug has completed one Phase 1 trial, NCT07211607, which enrolled 40 healthy adult subjects in the United States. As an investigational drug, it has not yet received FDA approval and remains in clinical testing.
Selonabant has been studied in one completed Phase 1 clinical trial, NCT07211607, titled "I.V. Selonabant in Healthy Adult Subjects." The trial enrolled 40 healthy volunteers in the United States and was a randomized, double-blind, controlled study. There are no active trials currently listed.
Selonabant is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The drug has completed a Phase 1 trial in healthy volunteers, but it has not been approved for any medical use by the FDA or any other regulatory authority.